| Literature DB >> 35067623 |
Min Ji Kim1, Hee Jung Seo1, Hong Mo Koo1, Minsu Ock, Jee-In Hwang2, Sang-Il Lee3.
Abstract
OBJECTIVES: We aimed to examine the Korea National Patient Safety Incidents Inquiry conducted in the Republic of Korea; specifically, we assessed the validity of screening criteria, interreviewer reliability, quality of medical records, and the time required for reviewing medical records.Entities:
Mesh:
Year: 2022 PMID: 35067623 PMCID: PMC9329038 DOI: 10.1097/PTS.0000000000000964
Source DB: PubMed Journal: J Patient Saf ISSN: 1549-8417 Impact factor: 2.243
Frequency and Sensitivity of Screening Criteria
| Screening Criteria | Patients of Second Stage Review, n (%) | Sensitivity, % | Positive Predictive Value, % |
|---|---|---|---|
| [General: admission, discharge, and transfer] | |||
| 1. The index admission was an unplanned admission related to previous healthcare management | 765 (5.1) | 10.2 | 13.1 |
| 2. Length of index was more than 30 d | 1667 (11.2) | 34.9 | 28.6 |
| 3. Unplanned readmission after discharge from index admission | 798 (5.4) | 14.5 | 17.1 |
| 4. Revisiting emergency department within 72 h after discharge from index admission | 180 (1.2) | 3.9 | 18.7 |
| 5. Unplanned transfer to another acute care hospital | 320 (2.2) | 5.2 | 18.3 |
| 6. Temperature higher than 38.3°C at the point of discharge | 44 (0.3) | 1.1 | 24.2 |
| 7. Unplanned transfer from general care to intensive care | 181 (1.2) | 7.4 | 41.0 |
| 8. Specialty consult | 2262 (15.2) | 42.0 | 19.4 |
| [Events] | |||
| 9. Cardiac or respiratory arrest, rapid response team activation | 152 (1.0) | 5.2 | 34.2 |
| 10. Death in hospital | 661 (4.4) | 10.1 | 22.3 |
| 11. Hospital incurred patient injury | 442 (3.0) | 29.3 | 69.4 |
| 12. Oversedation/hypotension | 268 (1.8) | 9.4 | 33.5 |
| 13. Restraint use | 439 (3.0) | 11.1 | 28.8 |
| 14. Acute dialysis | 11 (0.1) | 0.3 | 25.0 |
| 15. In-unit procedure | 1329 (8.9) | 30.6 | 26.1 |
| 16. Treatment of organ damage after an invasive procedure | 19 (0.1) | 1.3 | 71.4 |
| 17. Acute myocardial infarction, cerebrovascular accident, or pulmonary embolus during or after an invasive procedure | 7 (0.0) | 0.4 | 42.9 |
| [Drug, fluid, blood] | |||
| 18. Transfusion or use of blood products | 1,463 (9.8) | 31.7 | 30.0 |
| 19. Peniramin injection (chlorpheniramine maleate 4 mg) or Chlorpheniramine Maleate Injection Huons (chlorpheniramine maleate 4 mg) use by intramuscular or intravenous route | 170 (1.1) | 7.4 | 43.0 |
| 20. Abrupt medication stop | 853 (5.7) | 25.0 | 28.4 |
| 21. Antidotes use | 86 (0.6) | 0.5 | 6.6 |
| 22. Adverse drug reaction | 230 (1.5) | 14.4 | 59.4 |
| [Test result] | |||
| 23. Health care–associated infection | 351 (2.4) | 15.0 | 43.8 |
| 24. Decrease in hemoglobin or hematocrit of 25% or greater | 917 (6.2) | 26.2 | 28.9 |
| 25. Hypoglycemic symptom | 185 (1.2) | 5.0 | 27.2 |
| 26. Bleeding tendency | 52 (0.3) | 2.0 | 32.6 |
| 27. Rising BUN or serum creatine >2 times baseline | 441 (3.0) | 9.5 | 19.3 |
| 28. | 70 (0.5) | 4.0 | 63.8 |
| [Related surgery] | |||
| 29. Postoperative troponin level greater than upper normal limit | 14 (0.1) | 0.7 | 45.5 |
| 30. Mechanical ventilation >24 h postoperatively | 14 (0.1) | 1.1 | 80.0 |
| 31. Unplanned return to the operating theater | 36 (0.2) | 2.4 | 64.3 |
| 32. Unplanned removal, injury, or repair of organ during surgery | 2 (0.0) | 0.1 | 50.0 |
| 33. Intraoperative epinephrine, norepinephrine, naloxone, or romazicon | 127 (0.9) | 2.8 | 22.1 |
| 34. Unplanned change in procedure or surgery | 22 (0.1) | 0.7 | 29.4 |
| 35. Intubation, reintubation, BiPap in postanesthesia care unit | 2 (0.0) | 0.0 | 0.0 |
| 36. X-ray in postanesthesia care unit | 1 (0.0) | 0.0 | 0.0 |
| [Obstetrics and neonates] | |||
| 37. β2 Agonist use in obstetrics | 0 (0.0) | — | — |
| 38. Oxytocic agents in obstetrics | 116 (0.8) | 0.3 | 3.1 |
| 39. Complications of neonatal, abortion, amniocentesis or labor and delivery | 0 (0.0) | — | — |
| [Others] | |||
| 40. Documentation or correspondence indicating litigation, dissatisfaction | 49 (0.3) | 1.6 | 28.6 |
| 41. Any other undesirable outcomes not covered above | 125 (0.8) | 7.9 | 51.3 |
| Total | 14,871 (100.0) | — | 17.9 |
Reliability of First Reviewers by Medical Institution
| Medical Institution | Overall Percent Agreement (Including All Negative Findings) | Overall Percent Agreement (Excluding All Negative Findings) | 95% CI | |
|---|---|---|---|---|
| A | 92.4 | 83.4 | 0.84 | 0.76–0.93 |
| B | 62.0 | 48.2 | 0.31 | 0.24–0.38 |
| C | 90.8 | 68.9 | 0.75 | 0.67–0.84 |
| D | 85.8 | 76.1 | 0.72 | 0.63–0.80 |
| E | 86.0 | 74.2 | 0.72 | 0.63–0.81 |
| F | 71.4 | 49.6 | 0.42 | 0.34–0.51 |
| G | 74.4 | 59.2 | 0.49 | 0.41–0.58 |
| H | 83.8 | 64.8 | 0.66 | 0.57–0.74 |
| I | 78.6 | 68.8 | 0.57 | 0.48–0.65 |
| J | 83.0 | 63.4 | 0.64 | 0.56–0.73 |
| K | 83.2 | 70.2 | 0.66 | 0.58–0.75 |
| L | 85.4 | 76.2 | 0.71 | 0.62–0.79 |
| M | 72.0 | 49.6 | 0.45 | 0.37–0.53 |
| N | 95.0 | 84.1 | 0.88 | 0.79–0.97 |
| O | 84.0 | 81.0 | 0.57 | 0.49–0.65 |
| Total | 81.9 | 67.3 | 0.64 | 0.61–0.66 |
Reliability of Second Reviewers by Medical Institution
| Medical Institution | Patients Who Progressed to Second Stage Review | Perfect Match* | Partial Match† | ||||
|---|---|---|---|---|---|---|---|
| n | Overall Percent Agreement | CI | Overall Percent Agreement | CI | |||
| A | 229 | 79.5 | 0.12 | −0.03 to 0.27 | 83.8 | 0.40 | 0.25 to 0.55 |
| B | 367 | 83.7 | 0.09 | −0.02 to 0.20 | 85.8 | 0.27 | 0.14 to 0.41 |
| C | 148 | 80.4 | −0.08 | −0.13 to −0.04 | 87.2 | 0.45 | 0.24 to 0.65 |
| D | 297 | 94.3 | 0.08 | −0.11 to 0.27 | 95.3 | 0.34 | 0.08 to 0.60 |
| E | 271 | 81.9 | 0.21 | 0.06 to 0.36 | 86.0 | 0.46 | 0.31 to 0.60 |
| F | 284 | 82.4 | 0.05 | −0.08 to 0.18 | 83.8 | 0.18 | 0.03 to 0.33 |
| G | 314 | 80.3 | 0.13 | 0.00 to 0.27 | 82.8 | 0.30 | 0.16 to 0.44 |
| H | 230 | 57.8 | 0.01 | −0.09 to 0.11 | 73.0 | 0.41 | 0.29 to 0.53 |
| I | 343 | 83.4 | 0.06 | −0.06 to 0.19 | 84.5 | 0.17 | 0.03 to 0.31 |
| J | 232 | 79.3 | 0.38 | 0.24 to 0.52 | 84.5 | 0.57 | 0.45 to 0.70 |
| K | 282 | 97.5 | −0.01 | −0.02 to 0.00 | 97.5 | −0.01 | −0.02 to 0.00 |
| L | 307 | 80.8 | 0.09 | −0.03 to 0.21 | 82.1 | 0.19 | 0.06 to 0.32 |
| M | 278 | 95.0 | 0.28 | 0.02 to 0.54 | 95.3 | 0.36 | 0.10 to 0.63 |
| N | 157 | 96.8 | 0.27 | −0.17 to 0.71 | 98.7 | 0.79 | 0.52 to 1.07 |
| O | 420 | 90.5 | 0.36 | 0.21 to 0.52 | 91.7 | 0.48 | 0.33 to 0.62 |
| Total | 4159 | 84.6 | 0.16 | 0.12 to 0.20 | 87.4 | 0.39 | 0.35 to 0.43 |
*Agreement in all of the opinions for the occurrence of an adverse event, the degree of harm, the causality, and the preventability.
†Agreement on the decision for adverse event but disagreement in the degree of harm, causality, or preventability.
Quality of Medical Record by Medical Institution
| Medical Institution | First Stage Review, Mean ± SD | Second Stage Review*, Mean ± SD |
|---|---|---|
| A | 3.12 ± 0.33 | 3.21 ± 0.41 |
| B | 2.93 ± 0.27 | 2.72 ± 0.48 |
| C | 3.06 ± 0.24 | 3.30 ± 0.56 |
| D | 3.51 ± 0.50 | 3.05 ± 0.38 |
| E | 3.10 ± 0.31 | 3.01 ± 0.11 |
| F | 3.37 ± 0.48 | 3.10 ± 0.37 |
| G | 3.06 ± 0.34 | 2.90 ± 0.30 |
| H | 3.52 ± 0.50 | 3.25 ± 0.46 |
| I | 3.00 ± 0.05 | 2.99 ± 0.11 |
| J | 3.00 ± 0.15 | 2.86 ± 0.37 |
| K | 3.39 ± 0.54 | 2.67 ± 0.50 |
| L | 3.02 ± 0.22 | 3.00 ± 0.00 |
| M | 3.48 ± 0.50 | 3.05 ± 0.21 |
| N | 3.24 ± 0.44 | 3.00 ± 0.00 |
| O | 3.00 ± 0.03 | 2.99 ± 0.11 |
| Total | 3.19 ± 0.42 | 3.05 ± 0.39 |
*Detailed adverse event reports only.
Review Time of First and Second Stage Review by Medical Institution
| Medical Institution | First Stage Review, Mean ± SD | Second Stage Review, Mean ± SD | Detailed Adverse Event Reports, Mean ± SD |
|---|---|---|---|
| A | 7.98 ± 12.90 | 3.96 ± 45.23 | 9.57 ± 8.59 |
| B | 6.35 ± 8.18 | 4.50 ± 5.86 | 6.54 ± 5.48 |
| C | 8.46 ± 21.15 | 2.02 ± 3.73 | 7.18 ± 6.39 |
| D | 10.68 ± 21.83 | 0.68 ± 4.10 | 11.47 ± 10.51 |
| E | 12.57 ± 12.61 | 3.05 ± 5.22 | 7.17 ± 9.76 |
| F | 8.92 ± 17.30 | 0.57 ± 1.41 | 3.39 ± 1.66 |
| G | 9.54 ± 16.23 | 22.50 ± 31.56 | 29.04 ± 45.31 |
| H | 17.96 ± 30.82 | 2.87 ± 4.75 | 5.45 ± 5.44 |
| I | 16.75 ± 20.61 | 5.51 ± 18.19 | 20.01 ± 49.53 |
| J | 8.32 ± 6.92 | 5.41 ± 9.93 | 8.87 ± 7.58 |
| K | 6.84 ± 6.35 | 0.62 ± 2.42 | 6.44 ± 3.13 |
| L | 9.71 ± 9.98 | 3.65 ± 6.66 | 9.29 ± 5.05 |
| M | 16.43 ± 33.48 | 14.95 ± 41.84 | 18.00 |
| N | 52.50 ± 130.40 | 1.71 ± 3.00 | 6.30 ± 4.50 |
| O | 8.39 ± 11.03 | 2.22 ± 4.94 | 6.60 ± 4.36 |
| Total | 13.02 ± 37.63 | 5.06 ± 19.10 | 9.47 ± 20.12 |